Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CHEMOIMMUNE: pembrolizumab plus metronomic cyclophosphamide in lymphopenic metastatic breast cancer
2016-002736-33Phase 2Completed
- Sponsor
- Centre Léon Bérard
- Start
- May 2017
- Modality
- Small Molecules, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab, cyclophosphamide in breast cancer, sponsored by Centre Léon Bérard. Started May 2017; status: completed.
02
Drugs
pembrolizumabcyclophosphamide
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2016-002736-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-002736-33.